866-997-4948(US-Canada Toll Free)

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 38 Pages

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016, provides in depth analysis on Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted pipeline therapeutics.

The report provides comprehensive information on the Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2)
- The report reviews Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) Overview 6
Therapeutics Development 7
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Stage of Development 7
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Therapy Area 8
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Indication 9
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Companies 12
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Products under Development by Universities/Institutes 14
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Companies Involved in Therapeutics Development 22
Amgen Inc. 22
Ascendis Pharma A/S 23
Ono Pharmaceutical Co., Ltd. 24
Sanofi 25
Santen Pharmaceutical Co., Ltd. 26
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Drug Profiles 27
omidenepag isopropyl - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ONO-8055 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SAR-366234 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecule to Antagonize EP2 Receptor for Alzheimer's Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TG-4155 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
treprostinil - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Dormant Projects 34
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Discontinued Products 35
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Featured News & Press Releases 36
Apr 28, 2015: Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 36
Jan 14, 2015: Ascendis Pharma Announces Initiation of a Phase 1 Single Ascending Dose Study of TransCon Treprostinil 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Amgen Inc., H2 2016 22
Pipeline by Ascendis Pharma A/S, H2 2016 23
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 24
Pipeline by Sanofi, H2 2016 25
Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 26
Dormant Projects, H2 2016 34
Discontinued Products, H2 2016 35

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *